OncoMatch/Clinical Trials/NCT06473961
A Phase Ib Study of GC101 in NSCLC
Is NCT06473961 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Autologous Tumor Infiltrating Lymphocytes for non small cell lung cancer metastatic.
Treatment: Autologous Tumor Infiltrating Lymphocytes — 20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Patients with unresectable advanced, recurrent, or metastatic non-small cell lung cancer; at least 1 measurable lesion (according to RECIST1.1 criteria)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: targeted therapy
have failed after targeted ... chemotherapy
Must have received: platinum-based chemotherapy
have failed after ... platinum-containing dual chemotherapy
Cannot have received: systemic therapy
More than 5-line system therapy had been used in previous 3 years before screening period
Cannot have received: cellular therapy
receipt of a comparable cellular therapy within 28 days prior to infusion
Lab requirements
Blood counts
WBC ≥2.5×10^9/L; ANC ≥1.5×10^9/L; ALC ≥0.7×10^9/L; Platelet ≥100×10^9/L; INR ≤1.5×ULN; APTT ≤1.5×ULN
Kidney function
Serum Creatinine ≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance ≥60mL/min; Urine protein <2+, or 24-hour urine protein <1g
Liver function
ALT/AST ≤3×ULN; Total Bilirubin ≤1.5×ULN
Cardiac function
NYHA class III or IV congestive heart failure with ejection fraction <50% excluded; severe cardiac rhythm or conduction abnormalities excluded; ECG QTcF ≥450ms excluded
With sufficient hematology and end-organ function as defined by the following laboratory test results ... see inclusion criterion 8 and exclusion criterion 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06473961 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy, cellular therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages